The chaperone-assisted selective autophagy complex dynamics and dysfunctions

Autophagy. 2023 Jun;19(6):1619-1641. doi: 10.1080/15548627.2022.2160564. Epub 2023 Jan 3.

Abstract

Each protein must be synthesized with the correct amino acid sequence, folded into its native structure, and transported to a relevant subcellular location and protein complex. If any of these steps fail, the cell has the capacity to break down aberrant proteins to maintain protein homeostasis (also called proteostasis). All cells possess a set of well-characterized protein quality control systems to minimize protein misfolding and the damage it might cause. Autophagy, a conserved pathway for the degradation of long-lived proteins, aggregates, and damaged organelles, was initially characterized as a bulk degradation pathway. However, it is now clear that autophagy also contributes to intracellular homeostasis by selectively degrading cargo material. One of the pathways involved in the selective removal of damaged and misfolded proteins is chaperone-assisted selective autophagy (CASA). The CASA complex is composed of three main proteins (HSPA, HSPB8 and BAG3), essential to maintain protein homeostasis in muscle and neuronal cells. A failure in the CASA complex, caused by mutations in the respective coding genes, can lead to (cardio)myopathies and neurodegenerative diseases. Here, we summarize our current understanding of the CASA complex and its dynamics. We also briefly discuss how CASA complex proteins are involved in disease and may represent an interesting therapeutic target.Abbreviation ALP: autophagy lysosomal pathway; ALS: amyotrophic lateral sclerosis; AMOTL1: angiomotin like 1; ARP2/3: actin related protein 2/3; BAG: BAG cochaperone; BAG3: BAG cochaperone 3; CASA: chaperone-assisted selective autophagy; CMA: chaperone-mediated autophagy; DNAJ/HSP40: DnaJ heat shock protein family (Hsp40); DRiPs: defective ribosomal products; EIF2A/eIF2α: eukaryotic translation initiation factor 2A; EIF2AK1/HRI: eukaryotic translation initiation factor 2 alpha kinase 1; GABARAP: GABA type A receptor-associated protein; HDAC6: histone deacetylase 6; HSP: heat shock protein; HSPA/HSP70: heat shock protein family A (Hsp70); HSP90: heat shock protein 90; HSPB8: heat shock protein family B (small) member 8; IPV: isoleucine-proline-valine; ISR: integrated stress response; KEAP1: kelch like ECH associated protein 1; LAMP2A: lysosomal associated membrane protein 2A; LATS1: large tumor suppressor kinase 1; LIR: LC3-interacting region; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MTOC: microtubule organizing center; MTOR: mechanistic target of rapamycin kinase; NFKB/NF-κB: nuclear factor kappa B; NFE2L2: NFE2 like bZIP transcription factor 2; PLCG/PLCγ: phospholipase C gamma; polyQ: polyglutamine; PQC: protein quality control; PxxP: proline-rich; RAN translation: repeat-associated non-AUG translation; SG: stress granule; SOD1: superoxide dismutase 1; SQSTM1/p62: sequestosome 1; STUB1/CHIP: STIP1 homology and U-box containing protein 1; STK: serine/threonine kinase; SYNPO: synaptopodin; TBP: TATA-box binding protein; TARDBP/TDP-43: TAR DNA binding protein; TFEB: transcription factor EB; TPR: tetratricopeptide repeats; TSC1: TSC complex subunit 1; UBA: ubiquitin associated; UPS: ubiquitin-proteasome system; WW: tryptophan-tryptophan; WWTR1: WW domain containing transcription regulator 1; YAP1: Yes1 associated transcriptional regulator.

Keywords: Aggresome; BAG3; HSPA; HSPB8; SQSTM1; STUB1; misfolding; myopathy; neurodegenerative diseases; neuropathy; proteostasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autophagy* / genetics
  • Heat-Shock Proteins / metabolism
  • Intracellular Signaling Peptides and Proteins / metabolism
  • Kelch-Like ECH-Associated Protein 1 / metabolism
  • Molecular Chaperones / metabolism
  • NF-E2-Related Factor 2* / metabolism
  • Ubiquitins / metabolism

Substances

  • Kelch-Like ECH-Associated Protein 1
  • NF-E2-Related Factor 2
  • Heat-Shock Proteins
  • Molecular Chaperones
  • Intracellular Signaling Peptides and Proteins
  • Ubiquitins

Grants and funding

This work was supported by the Agenzia Italiana del Farmaco, Ministero della Salute [Co_ALS]; Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica [MLOpathy; Target-RAN]; Fondazione Telethon [GGP19128]; French Muscular Dystrophy Association [23236]; Flanders Fund for Scientific Research [FWO-Flanders, n. G040821N]; Fondazione Regionale per la Ricerca Biomedica (FRRB) (Regione Lombardia) [TRANS_ALS, n. 2015–0023]; University of Antwerp [TOP-BOF, n. 38694; GOA n. 41667]; Ministero dell’Università e della Ricerca [PRIN 2017F2A2C5; CN3: RNA: CN_00000041; Dipartimento di Eccellenza]; American Muscular Dystrophy association (MDA) [577497]. The Flanders Fund for Scientific Research (FWO-Flanders, n. G040821N to VT), and Solve-RD (Horizon 2020 under grant agreement n. 779257 to VT as active partner). BT PhD fellowship was funded by FRRB (Regione Lombardia, TRANS_ALS, n. 2015–0023 to AP); LV obtained a PhD fellowship of FWO-Flanders, Belgium. VT is a member of the µNEURO Center of Excellence at the University of Antwerp.